Hubei Biocause Pharmaceutical Co., Ltd. operates in the Life insurance sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hubei Biocause Pharmaceutical Co., Ltd. with three other
insurance companies in Asia:
China Life Insurance Company Limited
sales of 268.23 billion Taiwanese Dollars [US$8.69 billion]
Mercuries & Associates Investment Ltd
(215.56 billion Taiwanese Dollars [US$6.98 billion]
Korean Reinsurance Company
based in South Korea
(9.01 trillion Korean Won [US$7.96 billion]
Sales increased substantially in 2017:
Hubei Biocause Pharmaceutical Co., Ltd. reported sales of 53.41 billion Chinese Renmimbi (US$7.68 billion)
December of 2017.
increase of 214.3%
versus 2016, when the company's sales were 16.99 billion Chinese Renmimbi.
Sales of Insurance saw an increase
408.4% in 2017, from
9.23 billion Chinese Renmimbi to 46.91 billion Chinese Renmimbi.